Embracing such personalized strategies can empower individuals to take control of their health and well-being, paving the way for a more balanced and fulfilling life during perimenopause
Its cardiovascular benefit data established in the SELECT trial (2023), demonstrating a significant reduction in major cardiovascular events in adults with obesity without diabetes is more mature than tirzepatides cardiovascular outcomes data, which is accumulating but more recent
keep weight loss gradual
Never share your semaglutide pen or needles with another person, even if the needle has been changed, as this poses serious infection risks
However, equally important is what happens when patients stop taking the drug
As a dual GIP and GLP-1 receptor agonist, tirzepatide simultaneously engages both incretin receptor pathways, differentiating it from single-pathway GLP-1 agents and underpinning the glycemic and weight loss outcomes observed across the SURPASS phase 3 program
